{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-018292","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.775625+00:00","generated_at":"2026-06-25T23:20:12.018391+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Curis Q1 net loss $16.1M; cash $120.7M; emavusertib studies on partial clinical hold","bullets":["Net loss $16.1M ($0.18/sh) vs $9.9M in Q1 2021; revenue $2.1M unchanged.","Cash and investments $120.7M; runway into 2024, guidance unchanged.","FDA partial clinical hold on TakeAim Leukemia and Lymphoma studies for emavusertib due to rhabdomyolysis data request.","TakeAim Leukemia data: 40% CR/CRh in spliceosome-mutated AML; 57% ORR in spliceosome-mutated MDS.","CI-8993 (anti-VISTA) dose escalation cleared 0.3mg/kg; now at 0.6mg/kg; RP2D yet to be determined."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-018292","json":"https://secwatch.observer/filing/0001564590-22-018292.json","markdown":"https://secwatch.observer/filing/0001564590-22-018292.md","text":"https://secwatch.observer/filing/0001564590-22-018292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000156459022018292/0001564590-22-018292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000156459022018292/cris-8k_20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:20:12.018391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}